EverHint – EMA 10 + Price + MACD – Top 8 Signals for Aug 18, 2026

Excerpt: 8 signals. Healthcare leads (3). price range $20-$418. 1 with insider selling.

What This Signal Is

Experimental strategy combining price crossing above EMA10 from below with MACD Line crossing above Signal Line from below. Both conditions must occur on the same day for a signal, providing double confirmation and higher-quality setups.

Entry Criteria:

• Buy: Price > EMA10 AND MACD line crosses above signal line
• Sell: Price < EMA10 AND MACD line crosses below signal line
• Minimum ADV: $40M (liquidity filter)
• Earnings buffer: 7 days pre/post earnings
• Fresh signal: All conditions met on today's close

Holding period: 1-3 weeks | Risk level: Medium-High

Market Context

Equity markets are experiencing a broad pullback on August 18, 2026, with technology-heavy indices bearing the brunt of selling pressure. The Nasdaq's decline of over 1.3% significantly outpaces the Dow's modest 0.22% dip, signaling that risk appetite is narrowing and traders are rotating away from growth-oriented names. This divergence suggests the market is not in a uniform risk-off mode, but rather undergoing a selective de-risking where high-multiple, momentum-driven sectors face the most headwinds. For EMA and MACD-based signals, this kind of uneven selling can create mixed crossover conditions, making signal quality more dependent on individual sector behavior than broad market direction.

Volatility, as measured by the VIX at 15.84 with a 4.28% intraday spike, remains in a moderate range but is trending upward. This level is not yet alarming, but the directional move higher warrants attention — rising VIX typically widens intraday price swings, which can both accelerate MACD divergences and trigger false EMA crossovers in choppier names. Traders relying on EMA-10 signals should expect slightly wider noise bands around entry points, making confirmation from MACD momentum particularly important before committing to a position.

The concentration of signals in the Healthcare sector is notable given today's macro backdrop. Healthcare tends to exhibit defensive characteristics, often attracting capital flows during periods of equity market stress and rising volatility. With growth sectors under pressure, the sector rotation dynamic appears to be favoring more stable, lower-beta areas — a tailwind for Healthcare-focused signals generated by trend-following strategies like EMA and MACD, which may find cleaner, more sustained directional moves in this environment compared to the broader market.

🟢 Buy Signals (8 of 8 total)

Ranked by RSI (lower RSI = more oversold for buy signals)

Field Notes

Sector concentration: Healthcare (3), Technology (2), Utilities (2)

Insider selling (7d): GDDY (GoDaddy Inc., -$17,240)

Data coverage: 12.5% insider (7d), 0.0% congressional (30d), 0.0% earnings, 25.0% news (7d)

Peer Analysis

GDDY (GoDaddy Inc.): Leads 5 peers: CPAY ($406.82), GEN ($27.64), CHKP ($130.31), NTNX ($65.83), VRSN ($276.74)

SPGI (S&P Global Inc.): Leads 5 peers: BAC ($64.23), SAN ($14.25), BLK ($1154.35), MCO ($485.79), TD ($121.97)

SRE (Sempra): Leads 5 peers: AEP ($126.35), VST ($140.52), D ($68.64), XEL ($79.17), EXC ($45.31)

TDC (Teradata Corporation): Leads 5 peers: NTCT ($38.94), MQ ($15.48), PGY ($20.32), EVTC ($29.59), CXM ($6.91)

UGI (UGI Corporation): Leads 5 peers: CMS ($71.06), SR ($83.13), IDA ($142.03), ELPC ($10.51), SWX ($91.71)

Recent Headlines

AMLX (Amylyx Pharmaceuticals, Inc.)

• Why Amylyx Pharmaceuticals Stock Skyrocketed Today
• Amylyx Pharmaceuticals Announces $350.0 Million Proposed Public Offering of Common Stock
• Amylyx stock soars on GLP-1 success: here's why investors should sell
• Amylyx Pharmaceuticals, Inc. (AMLX) Discusses Positive Phase III LUCIDITY Topline Results for Avexitide in Post-Bariatric Hypoglycemia Transcript
• Amylyx: Upgraded To Strong Buy On LUCIDITY Outcome, Avexitide, And 2026 Catalysts
• Amylyx Phase III Avexitide Trial Cuts Severe Hypoglycemic Events 55%
• Amylyx Pharmaceuticals Comes Closer to Potentially Delivering First Treatment for Weight Loss Surgery-Related Low Suger Level
• Amylyx Stock Surges 21% After GLP-1 Drug Succeeds in Phase 3 Trial

AZN (AstraZeneca PLC)

• AZN Ends NSCLC Study for Bispecific Antibody Over Unlikely Success
• AstraZeneca maintains Citi 'buy' rating despite mixed pipeline updates

Vlad's Take

Today's signals: Strong sector concentration in Healthcare (3 signals) suggests sector-specific rotation.

Independent, data-driven signals.
No hype. No promotions. Just experimental market research from EverHint.

This is not financial advice. Market conditions change rapidly.
Do your own due diligence.
See https://www.everhint.com/disclaimer/ and https://www.everhint.com/faqs/

📢 If you found this useful, a quick like, share, or subscribe keeps EverHint moving forward.